Kyowa Kirin Co., Ltd. (FRA:KY4)

Germany flag Germany · Delayed Price · Currency is EUR
12.90
+0.10 (0.78%)
At close: Oct 21, 2025
0.78%
Market Cap6.86B
Revenue (ttm)2.91B
Net Income (ttm)226.71M
Shares Outn/a
EPS (ttm)0.43
PE Ratio30.27
Forward PEn/a
Dividend0.35 (2.76%)
Ex-Dividend DateJun 27, 2025
Volumen/a
Average Volume19
Open12.90
Previous Close12.80
Day's Range12.90 - 12.90
52-Week Range12.30 - 15.50
Betan/a
RSI41.73
Earnings DateOct 30, 2025

About Kyowa Kirin

Kyowa Kirin Co., Ltd. engages in the research, development, manufacture, import/export, and market of pharmaceuticals products worldwide. The company offers Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; POTELIGEO for the treatment of cutaneous T-cell lymphoma; Nouriast/Nourianz, an adenosine A2A receptor antagonist; G-LASTA, a mobilization of hematopoietic stem cells into peripheral blood for autologous blood stem cell transplantation; Libmeldy/Lenmeldy for treating metachro... [Read more]

Industry Pharmaceutical Preparations
Founded 1949
Employees 5,669
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol KY4
Full Company Profile

Financial Performance

In 2024, Kyowa Kirin's revenue was 495.56 billion, an increase of 12.06% compared to the previous year's 442.23 billion. Earnings were 59.87 billion, a decrease of -26.26%.

Financial numbers in JPY Financial Statements

News

There is no news available yet.